α-D-mannofuranose | 41847-48-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: α-D-mannofuranose
• 英文别名: L-gulose；beta-L-Gulofuranose；(2S,3S,4R,5R)-5-[(1S)-1,2-dihydroxyethyl]oxolane-2,3,4-triol
• CAS: 41847-48-7
• 化学式: C₆H₁₂O₆
• 分子量: 180.158
• InChiKey: AVVWPBAENSWJCB-ZSNZIGRDSA-N

物化性质

• 沸点：
  476.9±45.0 °C(Predicted)
• 密度：
  1.777±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  110
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  α-D-mannofuranose 、 2,2-二甲氧基丙烷 在 对甲苯磺酸 作用下， 以 丙酮 为溶剂， 反应 36.0h， 以72%的产率得到2,3,5,6-di-O-isopropylidene-β-L-gulofuranose
  参考文献：
  名称：

  通过 Aziridino-γ-内酯方法学对保护的等价物 APTO、微硬皮素 C 和 D 的 β-氨基酸片段进行对映特异性合成

  摘要：

  (2S,3R,4S,5S,7E)-3-amino-8-phenyl-2,4,5-trihydroxyoct-7-enoic acid (APTO) 保护形式的有效合成，α-羟基 β-描述了从 lithistid 海绵中分离的 23 元环肽 microsclerodermins C 和 D 的氨基酸成分。该策略基于通过我们实验室先前为更简单的底物开发的程序从 L-gulose 制备氮丙啶-γ-内酯 46。乙酸根阴离子在 C-2 处区域选择性打开氮丙啶，这是氮丙啶-γ-内酯的内在反应模式，随后进行 Heck 反应以安装末端苯基，提供内酯 48。这是 APTO 的内酯化形式，可以是被认为是合成微硬皮素 C 和 D 或其类似物的活化构件，正如其随后与苄胺反应得到甲酰胺 51 所证明的那样。这代表了使用氮丙啶基-γ-内酯立体选择性合成 α-取代的 β-氨基酸衍生物的第一个例子。(© Wiley-VCH

  DOI：

  10.1002/ejoc.200801000

文献信息

• [EN] AN ANTIMICROBIAL AGENT<br/>[FR] AGENT ANTIMICROBIEN
  申请人：UNIV GRIFFITH

  公开号：WO2003097657A1

  公开（公告）日：2003-11-27

  The present invention relates to novel thioglycosides of D-galactofuranose that have an antimicrobial action, methods for their synthesis, pharmaceutical compositions containing them and methods for the treatment of patients suffering microbial infection.

  本发明涉及具有抗微生物作用的新型D-半乳糖苷，其合成方法，含有它们的药物组合物以及治疗患有微生物感染的患者的方法。
• MONOSACCHARIDE DERIVATIVES
  申请人：Sattigeri Jitendra Viswajanani

  公开号：US20080114031A1

  公开（公告）日：2008-05-15

  The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, Ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, Ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

  本发明涉及单糖衍生物作为抗炎剂。本发明的化合物可用于抑制和预防炎症及相关病理，包括炎症和自身免疫疾病，如支气管哮喘、类风湿性关节炎、I型糖尿病、多发性硬化症、异体移植排斥、银屑病、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒和过敏性鼻炎。还提供了包含本发明披露的化合物的药物组合物，以及使用这些化合物治疗支气管哮喘、慢性阻塞性肺病、类风湿性关节炎、多发性硬化症、I型糖尿病、银屑病、异体移植排斥、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒、过敏性鼻炎以及其他炎症性和/或自身免疫障碍的方法。
• Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds
  申请人：Sattigeri Viswajanani Jitendra

  公开号：US20090075909A1

  公开（公告）日：2009-03-19

  The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds of this invention can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and autoimmune diseases, for example, bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis. The present invention also relates to pharmacological compositions containing these monosaccharide derivatives, as well as methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, and other inflammatory and/or auto immune disorders.

  本发明涉及单糖衍生物作为抗炎药剂。本发明的化合物可用于抑制和预防炎症及相关病理，包括炎症性和自身免疫性疾病，例如支气管哮喘、类风湿关节炎、I 型糖尿病、多发性硬化症、移植排斥或牛皮癣。本发明还涉及含有这些单糖衍生物的药物组合物，以及治疗支气管哮喘、慢性阻塞性肺病、类风湿关节炎、多发性硬化症、I 型糖尿病、牛皮癣、移植排斥和其他炎症和/或自身免疫性疾病的方法。
• Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents
  申请人：Sattigeri Vishwajanani Jitendra

  公开号：US20090048186A1

  公开（公告）日：2009-02-19

  The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

  本发明涉及单糖衍生物作为抗炎剂。本发明的化合物可用于抑制和预防炎症及相关病理，包括炎症和自身免疫疾病，如支气管哮喘、类风湿性关节炎、I型糖尿病、多发性硬化症、异体移植排斥、银屑病、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒和过敏性鼻炎。还提供了含有本发明披露的化合物的药物组合物，以及使用这些化合物治疗支气管哮喘、慢性阻塞性肺病、类风湿性关节炎、多发性硬化症、I型糖尿病、银屑病、异体移植排斥、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒、过敏性鼻炎以及其他炎症性和/或自身免疫障碍的方法。
• Monosaccharide derivatives as anti-inflammatory agents
  申请人：Ranbaxy Laboratories Limited

  公开号：EP1953170A1

  公开（公告）日：2008-08-06

  The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory, cancer, cardiovascular and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type-I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, pruritis or allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating diseases such as bronchial asthma, rheumatoid arthritis, type-I diabetes, multiple sclerosis, cancer, cardiovascular diseases, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, pruritis or allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

  本发明涉及单糖衍生物作为抗炎药剂。本文披露的化合物可用于抑制和预防炎症及相关病理，包括炎症性、癌症、心血管和自身免疫疾病，如支气管哮喘、类风湿关节炎、I型糖尿病、多发性硬化症、移植排斥、牛皮癣、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、瘙痒或过敏性鼻炎。还提供了含有本文披露的化合物的药理组合物和治疗支气管哮喘、类风湿关节炎、I型糖尿病、多发性硬化症、癌症、心血管疾病、移植排斥、牛皮癣、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、瘙痒或过敏性鼻炎等疾病的方法，以及使用这些化合物治疗其他炎症性和/或自身免疫性疾病的方法。